Targeted expression of transforming growth factor-β1 in intracardiac grafts promotes vascular endothelial cell DNA synthesis

Young Koh Gou Young Koh, S. J. Kim, M. G. Klug, K. Park, Mark Soonpaa, Loren Field

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Intracardiac grafts comprised of genetically modified skeletal myoblasts were assessed for their ability to effect long-term delivery of recombinant transforming growth factor-β (TGF-β) to the heart. C2C12 myoblasts were stably transfected with a construct comprised of an inducible metallothionein promoter fused to a modified TGF-β1 cDNA. When cultured in medium supplemented with zinc sulfate, cells carrying this transgene constitutively secrete active TGF-β1. These genetically modified myoblasts were used to produce intracardiac grafts in syngeneic C3Heb/FeJ hosts. Viable grafts were observed as long as three months after implantation, and immunohistological analyses of mice maintained on water supplemented with zinc sulfate revealed the presence of grafted cells which stably expressed TGF-β1. Regions of apparent neovascularization, as evidenced by tritiated thymidine incorporation into vascular endothelial cells, were observed in the myocardium which bordered grafts expressing TGF-β1. The extent of vascular endothelial cell DNA synthesis could be modulated by altering dietary zinc. Similar effects on the vascular endothelial cells were not seen in mice with grafts comprised of nontransfected cells. This study indicates that genetically modified skeletal myoblast grafts can be used to effect the local, long-term delivery of recombinant molecules to the heart.

Original languageEnglish
Pages (from-to)114-121
Number of pages8
JournalJournal of Clinical Investigation
Volume95
Issue number1
StatePublished - 1995

Fingerprint

Transforming Growth Factors
Endothelial Cells
Transplants
DNA
Skeletal Myoblasts
Zinc Sulfate
Myoblasts
Metallothionein
Transgenes
Thymidine
Zinc
Myocardium
Complementary DNA
Water

Keywords

  • angiogenesis
  • C2C12 skeletal myoblasts
  • cell transplantation
  • gene therapy
  • intracardiac grafts
  • myocardial repair

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Targeted expression of transforming growth factor-β1 in intracardiac grafts promotes vascular endothelial cell DNA synthesis. / Gou Young Koh, Young Koh; Kim, S. J.; Klug, M. G.; Park, K.; Soonpaa, Mark; Field, Loren.

In: Journal of Clinical Investigation, Vol. 95, No. 1, 1995, p. 114-121.

Research output: Contribution to journalArticle

@article{26a62ba1936d4fcc8d94eee4842f2960,
title = "Targeted expression of transforming growth factor-β1 in intracardiac grafts promotes vascular endothelial cell DNA synthesis",
abstract = "Intracardiac grafts comprised of genetically modified skeletal myoblasts were assessed for their ability to effect long-term delivery of recombinant transforming growth factor-β (TGF-β) to the heart. C2C12 myoblasts were stably transfected with a construct comprised of an inducible metallothionein promoter fused to a modified TGF-β1 cDNA. When cultured in medium supplemented with zinc sulfate, cells carrying this transgene constitutively secrete active TGF-β1. These genetically modified myoblasts were used to produce intracardiac grafts in syngeneic C3Heb/FeJ hosts. Viable grafts were observed as long as three months after implantation, and immunohistological analyses of mice maintained on water supplemented with zinc sulfate revealed the presence of grafted cells which stably expressed TGF-β1. Regions of apparent neovascularization, as evidenced by tritiated thymidine incorporation into vascular endothelial cells, were observed in the myocardium which bordered grafts expressing TGF-β1. The extent of vascular endothelial cell DNA synthesis could be modulated by altering dietary zinc. Similar effects on the vascular endothelial cells were not seen in mice with grafts comprised of nontransfected cells. This study indicates that genetically modified skeletal myoblast grafts can be used to effect the local, long-term delivery of recombinant molecules to the heart.",
keywords = "angiogenesis, C2C12 skeletal myoblasts, cell transplantation, gene therapy, intracardiac grafts, myocardial repair",
author = "{Gou Young Koh}, {Young Koh} and Kim, {S. J.} and Klug, {M. G.} and K. Park and Mark Soonpaa and Loren Field",
year = "1995",
language = "English",
volume = "95",
pages = "114--121",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "1",

}

TY - JOUR

T1 - Targeted expression of transforming growth factor-β1 in intracardiac grafts promotes vascular endothelial cell DNA synthesis

AU - Gou Young Koh, Young Koh

AU - Kim, S. J.

AU - Klug, M. G.

AU - Park, K.

AU - Soonpaa, Mark

AU - Field, Loren

PY - 1995

Y1 - 1995

N2 - Intracardiac grafts comprised of genetically modified skeletal myoblasts were assessed for their ability to effect long-term delivery of recombinant transforming growth factor-β (TGF-β) to the heart. C2C12 myoblasts were stably transfected with a construct comprised of an inducible metallothionein promoter fused to a modified TGF-β1 cDNA. When cultured in medium supplemented with zinc sulfate, cells carrying this transgene constitutively secrete active TGF-β1. These genetically modified myoblasts were used to produce intracardiac grafts in syngeneic C3Heb/FeJ hosts. Viable grafts were observed as long as three months after implantation, and immunohistological analyses of mice maintained on water supplemented with zinc sulfate revealed the presence of grafted cells which stably expressed TGF-β1. Regions of apparent neovascularization, as evidenced by tritiated thymidine incorporation into vascular endothelial cells, were observed in the myocardium which bordered grafts expressing TGF-β1. The extent of vascular endothelial cell DNA synthesis could be modulated by altering dietary zinc. Similar effects on the vascular endothelial cells were not seen in mice with grafts comprised of nontransfected cells. This study indicates that genetically modified skeletal myoblast grafts can be used to effect the local, long-term delivery of recombinant molecules to the heart.

AB - Intracardiac grafts comprised of genetically modified skeletal myoblasts were assessed for their ability to effect long-term delivery of recombinant transforming growth factor-β (TGF-β) to the heart. C2C12 myoblasts were stably transfected with a construct comprised of an inducible metallothionein promoter fused to a modified TGF-β1 cDNA. When cultured in medium supplemented with zinc sulfate, cells carrying this transgene constitutively secrete active TGF-β1. These genetically modified myoblasts were used to produce intracardiac grafts in syngeneic C3Heb/FeJ hosts. Viable grafts were observed as long as three months after implantation, and immunohistological analyses of mice maintained on water supplemented with zinc sulfate revealed the presence of grafted cells which stably expressed TGF-β1. Regions of apparent neovascularization, as evidenced by tritiated thymidine incorporation into vascular endothelial cells, were observed in the myocardium which bordered grafts expressing TGF-β1. The extent of vascular endothelial cell DNA synthesis could be modulated by altering dietary zinc. Similar effects on the vascular endothelial cells were not seen in mice with grafts comprised of nontransfected cells. This study indicates that genetically modified skeletal myoblast grafts can be used to effect the local, long-term delivery of recombinant molecules to the heart.

KW - angiogenesis

KW - C2C12 skeletal myoblasts

KW - cell transplantation

KW - gene therapy

KW - intracardiac grafts

KW - myocardial repair

UR - http://www.scopus.com/inward/record.url?scp=0028889214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028889214&partnerID=8YFLogxK

M3 - Article

C2 - 7529257

AN - SCOPUS:0028889214

VL - 95

SP - 114

EP - 121

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 1

ER -